BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ANGLE plc - Parsortix, Inc. Update


6/28/2011 10:39:44 AM

June 28, 2011 -- Encouraging initial results for cancer cell isolation technology

ANGLE plc is pleased to provide a further update on its 80% owned portfolio company Parsortix Inc (“Parsortix”) which specialises in medical diagnostics.

Parsortix has developed an innovative separation platform technology for the isolation of cells in blood, including rare cells which occur in very low numbers, such as one cell within 500 million other cells.

As announced on 5 May 2011, ANGLE has been working with Parsortix seeking to demonstrate that the device has the capability to isolate cancer cells in blood.

Initial experiments have been successful in capturing cultured breast cancer cells that had been added to healthy whole blood. This “spiked blood” experiment is a pre-cursor to isolating cancer cells in cancer patient blood.

Whilst the results are encouraging, the experiments were early stage and are subject to further work in order to validate the initial findings which ANGLE is now undertaking. It is anticipated that this further work will be completed within three months.

The device has already been proven and independently verified to isolate intact foetal cells (as opposed to merely DNA fragments) in peripheral maternal blood. This offers the potential for non-invasive assessment of the health of the unborn child avoiding the current invasive techniques of amniocentesis and chorionic villi sampling.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

“There is currently significant medical interest in the potential for the isolation of CTCs (circulating tumour cells) in blood to improve the diagnosis and treatment of cancer.

“Although recognising that the initial experiments are preliminary in nature, we are encouraged by our progress with cancer cell isolation to date and are confident in completing the necessary validatory work required to progress this technology further.”

For further information:

ANGLE plc 01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Matt Goode

0207 523 8350

Buchanan

Lisa Baderoon, Catherine Breen

020 7466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->